OR4F15

Across TCGA pan-cancer cohorts, OR4F15 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated OR4F15 data layer compared with 12 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher OR4F15 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR4F15 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SCLC, COAD, and LIHC are the cancer types where OR4F15 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.164	0.662	<.001	24	view →
COAD	OS	Median	All	0.168	0.806	.002	18	view →
LIHC	OS	Median	All	0.118	0.783	<.001	18	view →
ACC	DFS	Median	All	0.195	0.748	.003	9	view →
UCEC	OS	Median	II,III,IV	1.000	0.466	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

OR4F15–SCLC (OS)

Open the SCLC breakdown →